import type { ReportEntry } from '@/data/healthcareReportTypes';

const SLUG = 'uae-cardiovascular-market-report';

/**
 * Curated copy for the UAE cardiovascular programmatic report.
 * Market sizing: BioNixus market analysis, 2026 (aligned with factRegistry: ~USD 400–460M 2026 → ~USD 618M 2030, ~11.7% CAGR).
 * Detail: MOHAP/DHA/DOH, mandatory insurance prior authorization, structural-heart and medical-tourism cardiac volumes.
 */
type OverrideCopy = Partial<ReportEntry> & Pick<ReportEntry, 'slug'>;

export const UAE_CARDIOVASCULAR_COPY: OverrideCopy = {
  slug: SLUG,
  title: 'UAE Cardiovascular Market Report 2026',
  metaTitle: 'UAE Cardiovascular Market Report 2026 | BioNixus',
  metaDescription:
    'UAE cardiovascular market ~USD 400–460M in 2026 (BioNixus analysis): MOHAP/DHA/DOH access, insurer prior authorization, NOAC/PCSK9/SGLT-2 growth, structural-heart (TAVI/MitraClip) and medical-tourism cardiac volumes—Gulf intelligence.',
  heroLead:
    'This briefing reads UAE cardiovascular care through its real access architecture: an insurance-funded private sector, three regulators, flagship structural-heart programmes, and a medical-tourism cardiac inflow that lifts procedural demand above resident epidemiology—mapping where insurer prior authorization, not registration, gates PCSK9 and newer therapy.',
  summaryPara1:
    'Cardiovascular disease is the leading cause of death in the UAE, driven by very high rates of diabetes, hypertension, dyslipidaemia, and obesity in both the national and expatriate populations. BioNixus sizes the cardiovascular market at roughly USD 400–460 million in 2026, advancing toward about USD 618 million by 2030 at roughly 11.7% CAGR. Demand is amplified by a premium, insurance-funded private sector and by medical-tourism cardiac surgery and structural-heart procedures (TAVI, MitraClip) concentrated at flagship centres. Access turns on the three-authority landscape (MOHAP federally, DHA in Dubai, DOH in Abu Dhabi) and on mandatory-insurance prior-authorization rules that differ by emirate and payer. Growth is led by NOACs displacing warfarin, PCSK9 and newer lipid-lowering agents, and SGLT-2 inhibitors in heart failure, while generics anchor the statin and legacy base. Sizing reflects BioNixus market analysis, 2026, applied alongside published CVD burden ranges rather than unaudited panel extrapolation.',
  summaryPara2:
    'Use this report with the [UAE healthcare market report](/uae-healthcare-market-report) for macro context, the [UAE medical devices market report](/uae-medical-devices-market-report) for structural-heart and cath-lab device dynamics, the [GCC cardiovascular market report](/market-reports/gcc-cardiovascular-market-report) for Gulf-wide benchmarking, the [Saudi Arabia cardiovascular market report](/market-reports/saudi-arabia-cardiovascular-market-report) for the larger neighbouring market, [cardiovascular therapy research](/healthcare-market-research/therapy/cardiovascular) for programme design, and the [healthcare market research hub](/healthcare-market-research) to scope bilingual fieldwork.',
  marketAccessNotes:
    'MOHAP federal registration plus DHA and DOH facility and procurement requirements; mandatory-insurance prior authorization and step rules for PCSK9 inhibitors and newer agents varying by emirate and payer (Thiqa, Daman, Dubai plans); NOAC growth displacing warfarin where monitoring is burdensome; SGLT-2 inhibitors expanding into heart failure on cardiorenal evidence shared with diabetes coverage; structural-heart (TAVI, MitraClip) and PCI volumes at flagship private and government centres anchoring antithrombotic and peri-procedural demand; medical-tourism cardiac surgery lifting procedural demand above resident epidemiology',
  fieldIntelligenceParagraph:
    'BioNixus field programmes treat UAE cardiovascular as an emirate-by-emirate, payer-by-payer system layered on a strong procedural engine. The same regimen can clear under one Abu Dhabi insurer and stall under a Dubai plan’s step rules, while government and premium private centres run different formulary logic. We pair bilingual cardiologist and pharmacist quantitative work with payer-medical-director depth, separate medical-tourism from resident demand so procedural volumes are not over-read, and map the structural-heart and PCI programmes that drive antithrombotic and peri-procedural use. Operational signals matter: warfarin-to-NOAC switching where monitoring is hard, insurer prior-authorization documentation for PCSK9 access, the cardiorenal overlap putting SGLT-2 inhibitors on both cardiology and diabetes coverage, and continuity-of-care considerations in a large expatriate population. KOL maps follow real procedural and guideline influence across the flagship institutions.',
  commercialOutlookParagraph:
    'The outlook to 2030 favours teams that win the insured premium channel and the procedural ecosystem without over-indexing on medical-tourism volume. The statin and legacy base stays under private-payer cost control; the growth sits in NOACs, PCSK9 and newer lipid agents (as prior-authorization pathways mature), and SGLT-2 inhibitors in heart failure. Manufacturers should plan emirate-specific access dossiers, insurer medical-policy engagement, and evidence packages that private payers increasingly expect, while aligning cardiology and diabetes narratives for the SGLT-2 overlap. Because a small number of insurers and flagship centres shape most premium and procedural volume, share assumptions should be stress-tested by emirate, payer archetype, and centre before regional revenue targets are locked.',
  methodologyParagraph:
    'Methodology combines BioNixus market analysis for sizing and CAGR bands with structured desk review of MOHAP, DHA, DOH, and insurer public guidance, plus primary modules—cardiologist and primary-care adoption surveys, payer and insurer medical-policy interviews, and centre-level procedural mapping where data is available. Epidemiology references use published UAE and regional cardiovascular burden ranges as planning inputs, separating resident from medical-tourism demand, and are not patient-level forecasts. Because emirate-level rules, insurer medical policies, and procedural capacity change on short cycles, access and pricing statements should be revalidated before launch decisions. Outputs are built for market access, medical affairs, and commercial leadership and do not constitute regulatory or clinical advice.',
  faqs: [
    {
      question: 'How large is the UAE cardiovascular market in 2026?',
      answer:
        'BioNixus market analysis sizes the UAE cardiovascular market at roughly USD 400–460 million in 2026, advancing toward about USD 618 million by 2030 at roughly 11.7% CAGR. Demand is amplified by an insurance-funded premium sector and by medical-tourism cardiac surgery and structural-heart procedures at flagship centres. Growth is led by NOACs, PCSK9 inhibitors, and SGLT-2 inhibitors in heart failure, while statins and legacy classes are under private-payer cost control. Use the GCC cardiovascular market report for Gulf-wide context and the UAE healthcare market report for macro sizing.',
    },
    {
      question: 'How does cardiovascular access work across the UAE’s three authorities?',
      answer:
        'MOHAP provides federal marketing authorisation, while DHA (Dubai) and DOH (Abu Dhabi) add facility and procurement requirements. MOHAP registration is the entry point, but real access for newer agents usually depends on emirate-level listing plus insurer prior authorization. For high-cost classes such as PCSK9 inhibitors, insurer medical policy and step rules are typically the binding constraint, and they differ by emirate and payer. Teams should map the sequence for each target emirate: MOHAP approval, DHA or DOH facility access, then insurer prior-authorization criteria.',
    },
    {
      question: 'Which cardiovascular classes are growing fastest in the UAE?',
      answer:
        'NOACs continue displacing warfarin, particularly where INR monitoring is inconvenient. PCSK9 inhibitors and newer lipid-lowering agents grow as insurer prior-authorization pathways mature. SGLT-2 inhibitors expand into heart failure on cardiorenal evidence, overlapping with diabetes coverage. Antithrombotic and peri-procedural demand rises with PCI and structural-heart procedures (TAVI, MitraClip) at flagship private and government centres. The statin and legacy antihypertensive base remains large but is dominated by generic and private-payer cost dynamics.',
    },
    {
      question: 'What role do structural heart and medical tourism play in UAE cardiology?',
      answer:
        'The UAE is a regional hub for advanced cardiac care, with high volumes of structural-heart procedures (TAVI, MitraClip) and cardiac surgery concentrated at flagship centres, partly driven by international patients. This lifts antithrombotic, anticoagulant, and peri-procedural pharmaceutical demand above what the resident population alone would generate. Because medical-tourism patients do not reflect the local payer mix, BioNixus separates resident from tourism-driven procedural demand so brand teams do not over-forecast addressable insured volume.',
    },
    {
      question: 'What local factors influence cardiovascular treatment in the UAE?',
      answer:
        'The high overlap of diabetes, hypertension, and obesity makes cardiorenal-metabolic management central, putting SGLT-2 inhibitors on both cardiology and diabetes coverage. Emirate-level insurer policy governs prior authorization and step rules. A large expatriate population adds continuity-of-care and language considerations, and Ramadan fasting influences adherence and dose timing for chronic therapy. BioNixus captures these payer, cultural, and procedural factors in qualitative work alongside prescribing surveys so plans reflect real initiation and reimbursable adherence rather than label assumptions.',
    },
    {
      question: 'How does BioNixus help cardiovascular teams win in the UAE?',
      answer:
        'BioNixus designs bilingual (Arabic–English) UAE cardiovascular programmes: cardiologist and primary-care adoption studies, insurer and payer medical-policy interviews, emirate-level access mapping across MOHAP, DHA, and DOH, NOAC and SGLT-2 switching analysis, and KOL mapping tied to real procedural and guideline influence. We separate resident from medical-tourism demand and align deliverables to launch, access, or switch-defence milestones, connecting UAE findings to GCC and global benchmarks only when a comparator truly informs governance. Typical outputs include emirate and payer archetypes, access-risk maps, switching analyses, and committee-ready executive summaries. Begin from the healthcare market research hub or request a scoped briefing through the contact page.',
    },
  ],
};
